A61P 27/06
Antiglaucoma agents or miotics
A61P27/06 (Antiglaucoma agents or miotics) appears on 5,238 US grants and 7,781 published applications in this corpus.
Search patents in A61P- Granted patents
- 5,238
- Published applications
- 7,781
- Assignees
- 1,995
- Inventors
- 11,711
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 2 | 0 |
| 1979 | 3 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 3 | 0 |
| 1984 | 5 | 0 |
| 1985 | 9 | 0 |
| 1986 | 2 | 0 |
| 1987 | 6 | 0 |
| 1988 | 9 | 0 |
| 1989 | 16 | 0 |
| 1990 | 16 | 0 |
| 1991 | 16 | 0 |
| 1992 | 11 | 0 |
| 1993 | 13 | 0 |
| 1994 | 17 | 0 |
| 1995 | 47 | 0 |
| 1996 | 43 | 0 |
| 1997 | 40 | 0 |
| 1998 | 37 | 0 |
| 1999 | 53 | 0 |
| 2000 | 53 | 0 |
| 2001 | 75 | 26 |
| 2002 | 114 | 149 |
| 2003 | 83 | 271 |
| 2004 | 98 | 338 |
| 2005 | 108 | 344 |
| 2006 | 144 | 378 |
| 2007 | 138 | 368 |
| 2008 | 159 | 424 |
| 2009 | 200 | 519 |
| 2010 | 264 | 597 |
| 2011 | 325 | 578 |
| 2012 | 348 | 505 |
| 2013 | 433 | 381 |
| 2014 | 376 | 357 |
| 2015 | 302 | 321 |
| 2016 | 246 | 360 |
| 2017 | 274 | 328 |
| 2018 | 266 | 264 |
| 2019 | 198 | 241 |
| 2020 | 167 | 213 |
| 2021 | 143 | 221 |
| 2022 | 96 | 153 |
| 2023 | 76 | 146 |
| 2024 | 85 | 142 |
| 2025 | 70 | 97 |
| 2026 | 46 | 60 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Topical ocular delivery of cromakalim6 Oct 2026US 12,751,939 B2Mayo Foundtation for Medical Education and Research
- Treatment of neurodegenerative eye disease using pridopidine22 Sep 2026US 12,740,973 B2Prilenia Neurotherapeutics Ltd.
- Use of high molecular weight hyaluronic acid as ocular transporting vehicle22 Sep 2026US 12,741,027 B2I. Com Medical GmbH
- Modulation of Wnt5a to treat glaucoma22 Sep 2026US 12,741,996 B2The Regents of the University of California
- Agent for treating myopia, preventing myopia and/or suppressing myopia progression25 Aug 2026US 12,714,715 B2Boehringer Ingelheim International GmbH
- Rock inhibitors and uses thereof1 Oct 2026US 2026/0297033 A1Alcon Inc.
- Modified sina molecules, methods and uses thereof17 Sep 2026US 2026/0275348 A1Phyzat Biopharmaceuticals, Lda.
- Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization10 Sep 2026US 2026/0263451 A1ADS Therapeutics LLC
- Adeno-associated virus pharmaceutical composition and use thereof27 Aug 2026US 2026/0248956 A1Chengdu Origen Biotechnology Co., Ltd.
- Treatment Of Glaucoma With Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) Inhibitors27 Aug 2026US 2026/0250681 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Noninvasive measurement of chemical substances433US 6,544,193 B22003
- Antibody compositions for selectively inhibiting VEGF356US 6,342,219 B12002
- Glaucoma treatment device355US 6,736,791 B1Glaukos Corporation · 2004
- Apparatus and method for treating glaucoma354US 6,638,239 B1Glaukos Corporation · 2003